Tetralogy of Fallot

Tetralogy of Fallot (TOF) is a complex congenital cardiac malformation characterized by the concurrent presence of four distinct anatomical abnormalities: (1) pulmonary stenosis (PS), typically infundibular, valvular, or supravalvular; (2) a large, non-restrictive ventricular septal defect (VSD) located in the perimembranous or infundibular region; (3) dextroposition of the aorta, which overrides the VSD and receives blood from both ventricles; and (4) concentric right ventricular hypertrophy (RVH) that develops as a consequence of the pressure overload imposed by the pulmonary stenosis and the systemic-level right ventricular pressure. This combination results in a right-to-left shunt, where deoxygenated blood bypasses the pulmonary circulation and enters the systemic circulation, leading to cyanosis, polycythemia, and exercise intolerance. TOF is the most common cyanotic congenital heart defect in dogs and is occasionally reported in cats. The severity of clinical signs is directly related to the degree of pulmonary outflow obstruction and the magnitude of the right-to-left shunt. In veterinary medicine, TOF is often classified as a cyanotic congenital heart disease, and its management focuses on alleviating hypoxemia, managing polycythemia, and addressing complications such as infective endocarditis and arrhythmias.

The exact etiology of Tetralogy of Fallot in veterinary patients is largely unknown, but it is considered to be a developmental defect arising from abnormal embryological development of the conotruncal region and the ventricular septum. The primary defect is thought to be anterior and cephalad deviation of the infundibular septum, which leads to malalignment of the aorta, a VSD, and obstruction of the right ventricular outflow tract. Genetic factors are strongly implicated, with a hereditary basis suspected in certain breeds, particularly the Keeshond, where a polygenic mode of inheritance has been proposed. In Keeshonds, a high incidence of conotruncal defects, including TOF, has been documented, suggesting a genetic predisposition. Other breeds with reported increased risk include the English Bulldog, Boxer, and German Shepherd, although the mode of inheritance is not clearly defined. Environmental teratogens, such as maternal exposure to certain drugs (e.g., corticosteroids, anticonvulsants) or infectious agents during pregnancy, have been hypothesized but not definitively proven in veterinary species. In cats, TOF is rare but has been reported in domestic shorthair and purebred cats, with no clear breed predisposition. The condition is congenital, meaning it is present at birth, and is not acquired later in life.

Tetralogy of Fallot is the most common cyanotic congenital heart defect in dogs, accounting for approximately 5-10% of all congenital cardiac anomalies in this species. It is less common in cats, representing a small fraction of feline congenital heart diseases. The condition is typically diagnosed in young animals, often before one year of age, but may be detected incidentally in older animals with mild clinical signs. Breed predispositions are notable: the Keeshond has a well-documented hereditary form, with a high prevalence in certain lines. Other breeds that may be overrepresented include the English Bulldog, Boxer, German Shepherd, and mixed-breed dogs. No consistent sex predilection has been reported, although some studies suggest a slight male predominance. In cats, no breed predilection is established, but the condition is occasionally seen in domestic shorthair cats. Geographic distribution is worldwide, with no seasonal variation. The incidence in the general canine population is estimated at less than 1%, but among dogs with congenital heart disease, TOF is relatively common. Early diagnosis is critical, as untreated animals may develop severe polycythemia, cyanotic episodes, and congestive heart failure, leading to reduced lifespan.

The pathophysiology of Tetralogy of Fallot is rooted in the four anatomical defects and their hemodynamic consequences. The large, non-restrictive VSD allows equalization of pressures between the left and right ventricles, resulting in right ventricular systolic pressure equal to systemic pressure. The pulmonary stenosis, which may be infundibular, valvular, or supravalvular, creates increased resistance to pulmonary blood flow. As a result, the right ventricle faces a high afterload, leading to concentric hypertrophy. Because the aorta overrides the VSD, it receives blood from both ventricles. The direction of shunting across the VSD depends on the relative resistances of the pulmonary and systemic circulations. In TOF, the pulmonary stenosis increases right ventricular outflow resistance, often exceeding systemic vascular resistance, leading to a right-to-left shunt. Deoxygenated blood from the right ventricle is ejected into the aorta, causing systemic arterial hypoxemia and cyanosis. The degree of cyanosis is proportional to the severity of pulmonary stenosis and the magnitude of the right-to-left shunt. Chronic hypoxemia stimulates erythropoietin production, leading to secondary polycythemia, which increases blood viscosity and can impair tissue perfusion, predisposing to thromboembolism. Right ventricular hypertrophy further compromises right ventricular compliance and may contribute to diastolic dysfunction. Over time, progressive infundibular stenosis can worsen, increasing the shunt and exacerbating clinical signs. In some animals, dynamic infundibular obstruction may cause transient 'tet spells' characterized by acute cyanosis and syncope, often triggered by stress, exercise, or increased sympathetic tone. The systemic circulation receives a mixture of oxygenated and deoxygenated blood, leading to variable arterial oxygen saturation, typically ranging from 60-90% depending on the shunt fraction. Secondary complications include infective endocarditis, particularly on the pulmonary valve or the VSD margins, and arrhythmias due to right ventricular hypertrophy and fibrosis.

Predisposing factors for Tetralogy of Fallot are primarily genetic and breed-related. The Keeshond breed has a well-established hereditary predisposition, with a polygenic mode of inheritance; breeding of affected or carrier animals increases the risk of producing offspring with TOF. Other breeds such as English Bulldogs, Boxers, and German Shepherds may have a genetic predisposition, although the exact inheritance pattern is not defined. In cats, no specific breed predisposition is identified, but the condition is congenital and may be associated with genetic mutations. Maternal factors during pregnancy, such as exposure to teratogenic drugs (e.g., corticosteroids, phenytoin) or infectious agents (e.g., canine parvovirus, feline panleukopenia), have been hypothesized to increase the risk of conotruncal defects, but evidence is limited. Nutritional deficiencies, such as vitamin A deficiency, have been implicated in experimental models but are not clinically relevant in well-managed pets. Age is a predisposing factor in that clinical signs typically manifest in young animals, but mild cases may go undetected until adulthood. Concurrent congenital anomalies, such as persistent right aortic arch or other cardiac defects, may be present and complicate the clinical picture. Additionally, animals with TOF are at increased risk for infective endocarditis, particularly if they undergo dental procedures or have concurrent infections, due to the turbulent blood flow and endothelial injury.

Clinical signs of Tetralogy of Fallot vary depending on the severity of pulmonary stenosis and the degree of right-to-left shunting. In mild cases, animals may be asymptomatic for months to years, with only a heart murmur detected on routine examination. In moderate to severe cases, clinical signs typically appear in young animals (3-6 months of age) and include: (1) Cyanosis, which is often more pronounced on mucous membranes and may be exacerbated by exercise or excitement; (2) Exercise intolerance, with affected animals tiring easily during physical activity; (3) Syncope or collapse, particularly during episodes of increased oxygen demand or stress ('tet spells'); (4) Dyspnea or tachypnea, especially after exertion; (5) Stunted growth or failure to thrive; (6) Polycythemia, which may manifest as ruddy or brick-red mucous membranes, and can lead to neurological signs such as seizures or ataxia due to hyperviscosity; (7) Heart murmur, typically a systolic ejection murmur best heard over the left heart base, due to pulmonary stenosis; a separate holosystolic murmur of the VSD may be heard over the right thorax, but is often masked by the right-to-left shunt; (8) Right ventricular hypertrophy may be palpable as a precordial thrill on the right side; (9) In advanced cases, signs of right-sided congestive heart failure (ascites, jugular venous distension, hepatomegaly) may develop, although this is less common than in other congenital defects; (10) Sudden death may occur due to arrhythmias or thromboembolism. In cats, clinical signs are similar but may include more pronounced respiratory distress and lethargy. The severity of cyanosis correlates with the degree of right-to-left shunt; animals with mild obstruction may have only exercise-induced cyanosis, while those with severe obstruction are persistently cyanotic.

Differential diagnoses for Tetralogy of Fallot include other cyanotic congenital heart defects and conditions that cause right-to-left shunting or pulmonary hypertension. Key differentials include: (1) Pulmonary stenosis with a patent foramen ovale (PFO) or atrial septal defect (ASD) leading to right-to-left shunt (Eisenmenger physiology); (2) Ventricular septal defect (VSD) with severe pulmonary hypertension (Eisenmenger syndrome); (3) Persistent truncus arteriosus, where a single great vessel overrides the VSD and gives rise to systemic, pulmonary, and coronary circulations; (4) Transposition of the great arteries (TGA), which is rare in dogs and cats; (5) Double outlet right ventricle (DORV), where both great arteries arise from the right ventricle; (6) Tricuspid atresia, which is often associated with a VSD and hypoplastic right ventricle; (7) Ebstein's anomaly, characterized by apical displacement of the tricuspid valve, leading to right atrial enlargement and right-to-left shunting through an ASD; (8) Pulmonary atresia with VSD, which is a severe form of TOF where the pulmonary valve is atretic; (9) Acquired pulmonary hypertension with right-to-left shunting through a pre-existing VSD or ASD, as seen in heartworm disease or chronic pulmonary disease; (10) Severe polycythemia due to other causes, such as chronic hypoxemia from respiratory disease or inappropriate erythropoietin production. Differentiation relies on echocardiography, which can definitively identify the four anatomical features of TOF and rule out other defects. Angiography or cardiac CT may be needed in complex cases. Clinical signs such as cyanosis and polycythemia are not specific to TOF and can occur in any right-to-left shunt.

The diagnostic approach to Tetralogy of Fallot should be systematic and stepwise. Step 1: Signalment and history – suspect TOF in young animals with cyanosis, exercise intolerance, and a heart murmur. Step 2: Physical examination – document cyanosis, heart murmur (systolic ejection at left base), and possible right precordial thrill. Step 3: Pulse oximetry – measure arterial oxygen saturation (SpO2); values below 90% on room air suggest right-to-left shunting. Step 4: Complete blood count (CBC) – look for polycythemia (elevated PCV, RBC count, and hemoglobin). Step 5: Thoracic radiography – may show right ventricular enlargement, a prominent main pulmonary artery segment (post-stenotic dilation), and decreased pulmonary vascularity. Step 6: Echocardiography – the gold standard for diagnosis; two-dimensional imaging reveals the VSD, overriding aorta, pulmonary stenosis, and right ventricular hypertrophy. Doppler echocardiography assesses the severity of pulmonary stenosis and the direction of shunting (right-to-left). Step 7: Electrocardiography (ECG) – may show right axis deviation, right ventricular hypertrophy patterns, and arrhythmias. Step 8: Advanced imaging – cardiac CT or MRI may be indicated for complex anatomy or when surgical planning is considered. Step 9: Blood gas analysis – arterial blood gas shows hypoxemia (low PaO2) and possibly metabolic acidosis. Step 10: Genetic testing – in breeds with known hereditary predisposition (e.g., Keeshond), genetic counseling may be offered, but no commercial test is widely available. Step 11: Rule out other congenital defects – a thorough echocardiographic examination should exclude other cyanotic lesions. Step 12: Assess for complications – evaluate for infective endocarditis (blood cultures, echocardiography for vegetations) and thromboembolism (imaging if neurological signs). The diagnostic algorithm should be tailored to the individual patient, but echocardiography is essential for definitive diagnosis.

Laboratory findings in Tetralogy of Fallot are primarily reflective of chronic hypoxemia and polycythemia. Complete blood count (CBC) typically reveals erythrocytosis: elevated red blood cell (RBC) count, hemoglobin concentration, and packed cell volume (PCV), often exceeding 55-65% in dogs. The white blood cell count and platelet count are usually within normal limits, unless there is concurrent infection or inflammation. Serum biochemistry may show mild elevations in liver enzymes (ALT, AST) due to hepatic congestion or hypoxic injury, and possibly increased total protein due to hemoconcentration. Blood gas analysis (arterial) demonstrates hypoxemia (PaO2 < 80 mmHg on room air) and decreased arterial oxygen saturation (SaO2). Metabolic acidosis may be present due to lactic acidosis from tissue hypoxia. Coagulation profiles may be abnormal in cases of hyperviscosity, with prolonged bleeding times due to platelet dysfunction. Serum erythropoietin levels may be elevated, but this test is not routinely performed. Urinalysis is typically unremarkable, but proteinuria may occur secondary to glomerular damage from hyperviscosity. Cardiac biomarkers such as NT-proBNP may be elevated due to myocardial stretch, but are not specific for TOF. In cases of infective endocarditis, blood cultures may be positive, and inflammatory markers (e.g., C-reactive protein) may be elevated. Genetic testing for known mutations is not commercially available, but research testing may be offered in certain institutions.

Imaging plays a crucial role in the diagnosis and assessment of Tetralogy of Fallot. Thoracic radiography (two views: right lateral and dorsoventral) typically shows: (1) Right-sided cardiomegaly, with increased sternal contact on the lateral view; (2) A prominent main pulmonary artery segment (post-stenotic dilation) on the dorsoventral view, although this may be absent if the stenosis is severe; (3) Decreased pulmonary vascularity (oligemia) due to reduced pulmonary blood flow; (4) A right aortic arch may be present in some cases, but this is not a consistent finding. Echocardiography is the definitive imaging modality. Two-dimensional (2D) echocardiography from the right parasternal long-axis view reveals the overriding aorta, a large VSD, and right ventricular hypertrophy. The pulmonary stenosis is best evaluated from the right parasternal short-axis view at the heart base, where the pulmonary valve and main pulmonary artery are visualized. Color-flow Doppler demonstrates turbulent flow across the pulmonary stenosis and right-to-left shunting across the VSD. Spectral Doppler can estimate the pressure gradient across the pulmonary stenosis, which is often elevated (>50 mmHg). Contrast echocardiography (bubble study) can confirm right-to-left shunting by visualizing microbubbles in the left heart after intravenous injection. Advanced imaging such as cardiac CT or MRI is rarely needed but may be useful for surgical planning, particularly to delineate the coronary anatomy and the exact morphology of the pulmonary outflow tract. CT angiography can provide detailed 3D reconstructions of the cardiac anatomy. In cases where echocardiography is inconclusive, cardiac catheterization with angiography may be performed, but this is invasive and rarely necessary in routine practice.

Cytology and histopathology are not typically used for the diagnosis of Tetralogy of Fallot, as the condition is a structural defect best diagnosed by imaging. However, histopathological examination of the heart may be performed post-mortem and reveals the four characteristic lesions: (1) A large VSD, typically in the perimembranous or infundibular region; (2) Overriding of the aorta, which is positioned above the VSD and receives blood from both ventricles; (3) Pulmonary stenosis, which may be valvular (thickened, fused cusps), subvalvular (infundibular hypertrophy), or supravalvular; (4) Concentric right ventricular hypertrophy, with increased wall thickness and myocyte hypertrophy. Histologically, the right ventricular myocardium shows hypertrophied myofibers with enlarged nuclei and increased interstitial fibrosis. The pulmonary valve may show myxomatous changes or fibrosis. In cases of infective endocarditis, vegetations may be present on the pulmonary valve or the VSD margins, composed of fibrin, platelets, and bacteria. Cytological examination of pericardial fluid or pleural effusion (if present) may show a modified transudate due to right-sided heart failure. However, these findings are non-specific and not diagnostic for TOF. In clinical practice, histopathology is rarely obtained antemortem, and the diagnosis is based on imaging findings.

Treatment of Tetralogy of Fallot is aimed at managing clinical signs, improving oxygenation, and preventing complications. Medical management is the mainstay for most patients, especially those with mild to moderate disease. Key components include: (1) Management of polycythemia: If PCV exceeds 65% and the animal is symptomatic (e.g., lethargy, ataxia), phlebotomy may be performed to reduce blood viscosity. The goal is to lower PCV to approximately 55-60%. A volume of blood equal to 10-20 ml/kg may be removed and replaced with an equal volume of isotonic crystalloids (e.g., 0.9% saline) to maintain vascular volume. This procedure should be done slowly and with caution to avoid hypotension. (2) Beta-blockers: Propranolol (0.2-1 mg/kg PO q8h) or atenolol (0.25-1 mg/kg PO q12h) may be used to reduce dynamic infundibular obstruction, decrease heart rate, and improve exercise tolerance. Beta-blockers are particularly useful in managing 'tet spells' by reducing right ventricular outflow tract obstruction. (3) Oxygen therapy: In acute cyanotic episodes, supplemental oxygen should be administered, but it is important to note that oxygen may not significantly improve arterial oxygenation in right-to-left shunts because the shunted blood bypasses the lungs. However, it can help with tissue oxygenation. (4) Management of congestive heart failure: If right-sided heart failure develops, diuretics such as furosemide (1-2 mg/kg IV or PO q8-12h) and ACE inhibitors such as enalapril (0.5 mg/kg PO q12h) may be used, but caution is needed because diuretics can worsen polycythemia by hemoconcentration. (5) Prevention of infective endocarditis: Antibiotic prophylaxis is recommended before dental or surgical procedures. Amoxicillin (22 mg/kg PO 1 hour before procedure) is commonly used. (6) Surgical treatment: Definitive surgical correction (intracardiac repair) is possible in specialized centers, but is associated with high morbidity and mortality in small animals. Palliative surgery, such as a Blalock-Taussig shunt (subclavian artery to pulmonary artery), may be performed to increase pulmonary blood flow, but is rarely done in veterinary practice. (7) Management of tet spells: Acute episodes of cyanosis and syncope should be treated with oxygen, sedation (e.g., butorphanol 0.2-0.4 mg/kg IV), and beta-blockers (e.g., propranolol 0.02-0.1 mg/kg IV slow). (8) Exercise restriction: Affected animals should be kept calm and avoid strenuous exercise to prevent hypoxemic episodes. (9) Nutritional support: A high-quality diet is essential, and supplementation with taurine may be considered in cats, although no specific dietary requirement is established for TOF. (10) Monitoring: Regular rechecks are necessary to assess PCV, oxygen saturation, and cardiac function.

The prognosis for Tetralogy of Fallot varies depending on the severity of the pulmonary stenosis and the degree of right-to-left shunting. Animals with mild obstruction and minimal shunting may have a relatively normal lifespan, with only mild exercise intolerance. However, most affected animals develop progressive clinical signs, and the median survival time without surgical intervention is reported to be around 1-3 years in dogs. Severe cases may die suddenly due to arrhythmias, thromboembolism, or hypoxemic episodes. Negative prognostic indicators include: (1) Severe polycythemia (PCV > 65%) at diagnosis; (2) Syncope or collapse; (3) Marked exercise intolerance; (4) Development of congestive heart failure; (5) Presence of arrhythmias; (6) Infective endocarditis. With medical management, many animals can have an acceptable quality of life for several years, but the disease is progressive. Surgical correction offers the potential for a better long-term outcome, but the perioperative mortality rate is high (20-40%) in veterinary patients, and the procedure is only available at specialized referral centers. In cats, the prognosis is generally poor, with most affected cats dying within the first year of life. Overall, the prognosis is guarded to poor, and owners should be counseled about the chronic nature of the disease and the need for lifelong monitoring and treatment.

Follow-up care for animals with Tetralogy of Fallot is essential to monitor disease progression and manage complications. Recommended schedule: (1) Recheck examinations every 3-6 months for stable patients, or more frequently if clinical signs worsen. At each visit, perform a thorough physical examination, including assessment of mucous membrane color, heart rate, respiratory rate, and auscultation for murmurs. (2) Monitor packed cell volume (PCV) every 3-6 months, or more frequently if polycythemia is severe. If PCV exceeds 65%, consider phlebotomy. (3) Pulse oximetry should be performed at each recheck to assess oxygen saturation. (4) Echocardiography should be repeated every 6-12 months to evaluate the severity of pulmonary stenosis, right ventricular hypertrophy, and shunt direction. (5) Electrocardiography (ECG) may be performed annually to screen for arrhythmias. (6) Blood pressure measurement is recommended to monitor for hypertension, which can exacerbate clinical signs. (7) Owners should be educated to recognize signs of tet spells (acute cyanosis, collapse) and to administer emergency treatment (oxygen, sedation, beta-blockers) as directed. (8) Dental prophylaxis should be performed regularly, with antibiotic prophylaxis before any procedure. (9) In animals on beta-blockers, monitor heart rate and blood pressure, and adjust dosage as needed. (10) If the animal develops signs of congestive heart failure (ascites, dyspnea), initiate appropriate therapy and recheck more frequently. (11) For animals that have undergone surgical correction, follow-up with a veterinary cardiologist is essential, with echocardiography at 1, 3, 6, and 12 months postoperatively, then annually. (12) Genetic counseling for breeding animals: affected animals should not be used for breeding, and parents of affected animals should be screened for subclinical cardiac defects.

Pearls: (1) Tetralogy of Fallot is the most common cyanotic congenital heart defect in dogs; always consider it in a young dog with cyanosis and a heart murmur. (2) The classic murmur is a systolic ejection murmur at the left heart base due to pulmonary stenosis; the VSD murmur may be absent or soft because of equalized ventricular pressures. (3) Polycythemia is a hallmark finding; a PCV > 60% in a young animal with cyanosis is highly suggestive of a right-to-left shunt. (4) Pulse oximetry is a quick, non-invasive tool to detect hypoxemia; SpO2 < 90% on room air is abnormal. (5) Echocardiography is the gold standard; look for the 'snowman' or 'boot-shaped' heart on radiographs, but confirm with echo. (6) Beta-blockers are the mainstay of medical therapy for tet spells; they reduce infundibular spasm. (7) Phlebotomy can provide rapid relief in severely polycythemic animals; always replace volume with crystalloids to avoid hypotension. (8) Antibiotic prophylaxis is crucial before dental procedures to prevent infective endocarditis. (9) Exercise restriction is important; stress can precipitate tet spells. (10) Prognosis is guarded, but with good medical management, some animals can live for several years. Pitfalls: (1) Do not administer diuretics aggressively in these patients, as they can worsen polycythemia and hypovolemia. (2) Do not rely solely on oxygen therapy for cyanosis; it is often ineffective in right-to-left shunts. (3) Avoid over-sedation, which can cause hypotension and worsen shunting. (4) Do not overlook the possibility of concurrent congenital defects; a thorough echocardiographic examination is essential. (5) Do not use ACE inhibitors as first-line therapy unless there is evidence of congestive heart failure; they may cause hypotension. (6) Do not perform phlebotomy too rapidly or remove too much blood; this can lead to shock. (7) Do not ignore the risk of thromboembolism; consider antithrombotic therapy (e.g., low-dose aspirin) in animals with severe polycythemia, but weigh the risk of bleeding. (8) Do not assume that a heart murmur is innocent; any murmur in a young animal warrants investigation. (9) Do not delay referral to a veterinary cardiologist for advanced imaging and management. (10) Do not breed affected animals or their parents, as the condition is hereditary in some breeds.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols are commonly used in the management of Tetralogy of Fallot: (1) Beta-blockers: Propranolol – Dosage: 0.2-1 mg/kg PO q8h; for acute tet spells, 0.02-0.1 mg/kg IV slow. Atenolol – 0.25-1 mg/kg PO q12h. These drugs reduce heart rate and myocardial contractility, and decrease infundibular spasm. (2) Sedatives for tet spells: Butorphanol – 0.2-0.4 mg/kg IV or IM; may be combined with a benzodiazepine such as diazepam (0.2-0.5 mg/kg IV). (3) Diuretics (if congestive heart failure): Furosemide – 1-2 mg/kg IV, IM, SC, or PO q8-12h; adjust based on response. (4) ACE inhibitors (if heart failure or hypertension): Enalapril – 0.5 mg/kg PO q12h; Benazepril – 0.25-0.5 mg/kg PO q24h. (5) Antibiotic prophylaxis for dental/surgical procedures: Amoxicillin – 22 mg/kg PO 1 hour before procedure; for penicillin-allergic patients, Clindamycin – 11 mg/kg PO 1 hour before procedure. (6) Antithrombotic therapy (in severe polycythemia): Aspirin (low-dose) – 0.5-1 mg/kg PO q24h in dogs; in cats, 5 mg (approximately 1/4 of a 81 mg tablet) PO q72h. Use with caution due to bleeding risk. (7) Oxygen therapy: Administer via flow-by or oxygen cage at 40-60% FiO2 during acute episodes. (8) Fluid therapy: During phlebotomy, replace removed blood with an equal volume of isotonic crystalloids (e.g., 0.9% NaCl) at a rate of 10-20 ml/kg over 30-60 minutes. (9) For chronic management, consider sildenafil (0.5-1 mg/kg PO q8-12h) in cases with pulmonary hypertension, although evidence is limited. (10) In cats, taurine supplementation (250-500 mg PO q12h) may be considered, but is not specific for TOF. All dosages should be adjusted based on renal/hepatic function, and drug interactions should be monitored, particularly with other cardiovascular drugs.

Evidence-based literature on Tetralogy of Fallot in veterinary medicine is limited, but several key studies and reviews provide guidance. A landmark study by Patterson et al. (1974) established the hereditary nature of conotruncal defects, including TOF, in Keeshonds, demonstrating a polygenic mode of inheritance. This study is foundational for understanding the genetic basis of the disease. A retrospective study by Tidholm et al. (1997) evaluated the clinical presentation and outcome of dogs with TOF, reporting a median survival time of 1.5 years in untreated dogs, with severe polycythemia and syncope being negative prognostic indicators. Another study by Chetboul et al. (2006) described the echocardiographic features of TOF in a cohort of dogs, emphasizing the importance of Doppler echocardiography in assessing the severity of pulmonary stenosis and shunt direction. In terms of treatment, a case series by Eyster et al. (1977) reported successful surgical correction of TOF in two dogs, but the high perioperative mortality rate (30-40%) has limited the widespread application of surgery. Medical management with beta-blockers has been supported by anecdotal evidence and extrapolation from human medicine; a study by Oyama et al. (2004) evaluated the use of atenolol in dogs with subaortic stenosis, but not specifically TOF. Consensus guidelines from the ACVIM (e.g., the 2015 ACVIM consensus statement on the diagnosis and treatment of canine chronic valvular heart disease) do not specifically address TOF, but provide general principles for managing congenital heart disease. A recent review by Saunders et al. (2018) summarized the current understanding of congenital heart defects in dogs and cats, highlighting the need for further research on TOF. Overall, the evidence base is limited, and most recommendations are based on expert opinion and extrapolation from human medicine. Future research should focus on genetic markers, optimal medical protocols, and surgical outcomes.